Opioids

Network for information about opioids

Moderators

Edie

International Society of Substance Use Professionals

Jose Luis Vazquez Martinez

CICAD/OAS

Discussions Fichiers Images Videos Liens Évènements Knowledge Share Tout

Fuente: https://nida.nih.gov/es/download/20630/el-fentanilo-drugfacts.pdf El fentanilo es un fuerte opioide sintético similar a la morfina, pero entre 50 y 100 veces más potente. Es un fármaco recetado que a veces también se usa en forma ilegal. Al igual que la morfina, por lo general se receta a...

El fentanilo, información de NIDA.pdf

Source: National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services. Fentanyl is a powerful synthetic opioid that is similar to morphine but is 50 to 100 times more potent. It is a prescription drug that is also made and used illegally. Like morphine...

fentanyl drugfacts NIDA.pdf

Source: Snowdon, J., & Choi, N. (2022). Unanticipated Changes in Drug Overdose Death Rates in Canada During the Opioid Crisis. International journal of mental health and addiction, 1–19. Advance online publication. https://doi.org/10.1007/s11469-022-00932-9

Unanticipated Changes in Drug Overdose Death Rates in Canada During the Opioid Crisis_0.pdf

Source: Marel, C., Wilson, J., Darke, S., Ross, J., Slade, T., Haber, P. S., Haasnoot, K., Visontay, R., Keaveny, M., Tremonti, C., Mills, K. L., & Teesson, M. (2023). Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence: Key Findings from the...

Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence - Key Findings from the 18-20-Year Follow-Up of the Australian Treatment Outcome Study (ATOS)_1.pdf

Fuente: https://www.fda.gov/news-events/press-announcements/la-fda-aprueba-una-nueva-opcion-de-tratamiento-con-buprenorfina-para-el-trastorno-por-consumo-de

Para publicación inmediata: 24 de mayo del 2023

Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó la inyección subcutánea (para uso por debajo de la piel) de Brixadi (buprenorfina) de liberación prolongada para tratar el trastorno por consumo de opioides (OUD, por sus siglas en inglés) de moderado a grave. Brixadi está disponible en dos formulaciones, una inyección semanal...

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder

For Immediate Release: May 23, 2023

Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, and...

Source: https://store.samhsa.gov/sites/default/files/pep23-02-01-002.pdf This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of...

Advisory Evidence-Based, Whole Person Care of Pregnant People Who Have Opioid Use Disorder_1.pdf

Source: Taylor EA, Cantor JH, Bradford AC, Simon K, Stein BD. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes. JAMA Netw Open. 2023;6(5):e2314328. doi:10.1001/jamanetworkopen.2023.14328 Key Points Question Did rates of methadone dispensing for opioid use...

Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes_0.pdf

Source: Jakubowski, A., Singh-Tan, S., Torres-Lockhart, K. et al. Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation. Addict Sci Clin Pract 18, 31 (2023). https://doi.org/10.1186/s13722-023-00386-x Abstract...

Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder opportunities for training innovation_0.pdf

Source: Onuoha, E. N., Leff, J. A., Schackman, B. R., McCollister, K. E., Polsky, D., & Murphy, S. M. (2021). Economic evaluations of pharmacologic treatment for opioid use disorder: a systematic literature review. Value in Health, 24(7), 1068-1083. Highlights There is new evidence on buprenorphine...

Click here → to read the full text

Ponente: Dr. Carlos Galicia Galicia Los objetivos del seminario son conocer el fentanilo de uso médico y diferenciarlo del producido clandestinamente. Además, presentar los fundamentos neurobiológicos del consumo compulsivo de fentanilo.

Source: Hooker, S. A., Crain, A. L., LaFrance, A. B., Kane, S., Fokuo, J. K., Bart, G., & Rossom, R. C. (2023). A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians. Addiction Science & Clinical Practice, 18(1), 1-10...

A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians_0.pdf

Source: Washburn LT, Franck KL, Upendram S and Yenerall JN (2022) Cooperative Extension professionals’ knowledge and attitudes toward the opioid epidemic: Implications for capacity development and outreach. Front. Psychiatry 13:958335. doi: 10.3389/fpsyt.2022.958335 Introduction: Worsening of the...

Cooperative Extension professionals' knowledge and attitudes toward the opioid epidemic Implications for capacity development and outreach.pdf

Source: Dolan AR, Goldberg EB, Cannuscio CC, et al. Patient Perceptions About Opioid Risk Communications Within the Context of a Randomized Clinical Trial. JAMA Netw Open. 2022;5(8):e2227650. doi:10.1001/jamanetworkopen.2022.27650 Key Points Question What can be learned about patient experiences...

Patient Perceptions About Opioid Risk Communications Within the Context of a Randomized Clinical Trial.pdf

Upcoming Events

There aren't any upcoming events

All Events

Opioids

El fentanilo, información de NIDA

Fentanyl DrugFacts

Unanticipated Changes in Drug Overdose Death Rates in Canada During the Opioid Crisis.

Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence: Key Findings from the 18-20-Year Follow-Up of the Australian Treatment Outcome Study (ATOS).

La FDA aprueba una nueva opción de tratamiento con buprenorfina para el trastorno por consumo de opioides

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

Advisory: Evidence-Based, Whole Person Care of Pregnant People Who Have Opioid Use Disorder

Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes

Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation

Summary

Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review

Buts et objectifs de la Conférence internationale sur la recherche

Fentanilo, de lo Molecular a lo Social - Dr. Carlos Galicia Galicia

A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians

Cooperative Extension professionals' knowledge and attitudes toward the opioid epidemic: Implications for capacity development and outreach

Patient Perceptions About Opioid Risk Communications Within the Context of a Randomized Clinical Trial

Upcoming Events